ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Antibody-drug Conjugate BMS-986517

Its studies are led by Bristol-Myers Squibb.

Furthest: phase 2, since Aug 29, 20251 company-led study, 1 open or runningNext primary completion: Jul 31, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb11 open or runningphase 2since Aug 29, 2025Aug 29, 2025Jul 31, 2028phase 2 · NCT07160725
  • Named in Bristol-Myers Squibb’s own pipeline as BMS-986517, phase 1, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 29, 2025First study: phase 2 study in Solid TumoursFirst studyNCT07160725 · 540 planned · United States, China, Denmark and more

Ahead

  1. Jul 31, 2028Primary completion: phase 2 study in Solid TumoursNCT07160725

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07160725Solid Tumours · United States, China, Denmark and more2RecruitingJul 31, 2028540

How it is read

Names in the registry

  • “BMS-986517”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
    Antibody-drug Conjugate BMS-986517 (Bristol-Myers Squibb): development program | ClinicalTrials.gg